Health Canada Issues Warning Against Possible Manufacturing Problem With Caninsulin

Health Canada has issued a warning relating to possible manufacturing problems with Caninsulin. Caninsulin is a drug aimed at treatment of diabetes in dogs and cats.

Health Canada and Intervet/Schering-Plough (manufactures of the product) have requested the customers to monitor patients, after receiving Caninsulin, for any changes in onset or duration of activity, or for any signs of hyperglycemia or hypoglycemia.

Intervet/Schering-Plough has stated that it is working with Health Canada to resolve the issue.

Caninsulin is an insulin zinc suspension product that may have varying amounts of crystalline zinc insulin in the formulation. This could cause a delay in insulin action and an overall longer duration of insulin activity. Products having significant problems with stability can affect the management of chronic diseases and in this case could lead to unpredictable fluctuations in the glucose levels of the treated animals.